Literature DB >> 17253926

A critical assessment of the directive on tissue engineering of the European union.

Leen Trommelmans1, Joseph Selling, Kris Dierickx.   

Abstract

The development of tissue engineering in Europe suffers from the absence of a coherent regulatory framework. Therefore, the European Commission has drafted a directive to regulate all tissue-engineered products in a comprehensive yet flexible framework. This article analyzes the directive from an ethical viewpoint. We argue that there are shortcomings to the proposal because of disjunctures at various regulatory levels and because responsibilities of several authorities have not been clearly established. The conscious decision to exclude ethically sensitive issues from the regulation will contribute to a continued complex regulatory environment for tissue-engineered products in Europe. We suggest that, from the start, ethical issues must be considered as an integral part of the regulation of tissue-engineered products. We propose the development of a multistage regulatory framework that makes provision for the diversity of tissue-engineered products, whereby the hybrid character and the ethical sensitivity of these products are fully taken into account. We equally suggest that the general public remain involved in regulatory issues concerning tissue-engineered products.

Mesh:

Year:  2007        PMID: 17253926     DOI: 10.1089/ten.2006.0089

Source DB:  PubMed          Journal:  Tissue Eng        ISSN: 1076-3279


  6 in total

1.  Burn patient care lost in good manufacturing practices?

Authors:  G Dimitropoulos; P Jafari; A de Buys Roessingh; N Hirt-Burri; W Raffoul; L A Applegate
Journal:  Ann Burns Fire Disasters       Date:  2016-06-30

2.  Towards a richer debate on tissue engineering: a consideration on the basis of NEST-ethics.

Authors:  A J M Oerlemans; M E C van Hoek; E van Leeuwen; S van der Burg; W J M Dekkers
Journal:  Sci Eng Ethics       Date:  2012-11-15       Impact factor: 3.525

3.  Business oriented EU human cell and tissue product legislation will adversely impact Member States' health care systems.

Authors:  Jean-Paul Pirnay; Alain Vanderkelen; Daniel De Vos; Jean-Pierre Draye; Thomas Rose; Carl Ceulemans; Nadine Ectors; Isabelle Huys; Serge Jennes; Gilbert Verbeken
Journal:  Cell Tissue Bank       Date:  2013-09-20       Impact factor: 1.522

4.  Biologicals and fetal cell therapy for wound and scar management.

Authors:  Nathalie Hirt-Burri; Albert-Adrien Ramelet; Wassim Raffoul; Anthony de Buys Roessingh; Corinne Scaletta; Dominique Pioletti; Lee Ann Applegate
Journal:  ISRN Dermatol       Date:  2011-05-18

Review 5.  Bone regeneration and stem cells.

Authors:  K Arvidson; B M Abdallah; L A Applegate; N Baldini; E Cenni; E Gomez-Barrena; D Granchi; M Kassem; Y T Konttinen; K Mustafa; D P Pioletti; T Sillat; A Finne-Wistrand
Journal:  J Cell Mol Med       Date:  2011-04       Impact factor: 5.310

6.  Ethical issues in cellular and molecular medicine and tissue engineering.

Authors:  Raymund E Horch; L M Pepescu; Charles Vacanti; Giovanni Maio
Journal:  J Cell Mol Med       Date:  2008-10       Impact factor: 5.310

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.